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Background: Endothelin-1 (ET-1) is a proinflammatory mediator and elevated in the regions of several brain injury
and inflammatory diseases. The deleterious effects of ET-1 on endothelial cells may aggravate brain inflammation
mediated through the regulation of cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) system in various cell types.
However, the signaling mechanisms underlying ET-1-induced COX-2 expression in brain microvascular endothelial
cells remain unclear. Herein we investigated the effects of ET-1 in COX-2 regulation in mouse brain microvascular
endothelial (bEnd.3) cells.
Results: The data obtained with Western blotting, RT-PCR, and immunofluorescent staining analyses showed that
ET-1-induced COX-2 expression was mediated through an ETB-dependent transcriptional activation. Engagement of
Gi- and Gq-protein-coupled ETB receptors by ET-1 led to phosphorylation of ERK1/2, p38 MAPK, and JNK1/2 and
then activated transcription factor NF-κB. Moreover, the data of chromatin immunoprecipitation (ChIP) and
promoter reporter assay demonstrated that the activated NF-κB was translocated into nucleus and bound to its
corresponding binding sites in COX-2 promoter, thereby turning on COX-2 gene transcription. Finally, up-regulation
of COX-2 by ET-1 promoted PGE2 release in these cells.
Conclusions: These results suggested that in mouse bEnd.3 cells, activation of NF-κB by ETB-dependent MAPK
cascades is essential for ET-1-induced up-regulation of COX-2/PGE2 system. Understanding the mechanisms of
COX-2 expression and PGE2 release regulated by ET-1/ETB system on brain microvascular endothelial cells may
provide rationally therapeutic interventions for brain injury or inflammatory diseases.
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Cerebral capillary and microvascular endothelial cells
play an active role in maintaining cerebral blood flow,
microvascular tone and blood-brain barrier (BBB) func-
tions [1]. In the development of various vascular dis-
eases, an early finding is dysfunction of the vascular
endothelium that is closely related to clinical events in
patients with atherosclerosis and hypertension [2,3]. The
vasoactive mediators such as endothelin (ET) could be
produced by endothelial cells to maintain hemodynamic
responses. Production and release of ETs from cultured* Correspondence: chuenmao@mail.cgu.edu.tw
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reproduction in any medium, provided the orendothelial cells are regulated at transcription and trans-
lation levels by a variety of chemical and physical stimuli
and the levels of ET, ET-1 especially, are elevated in
shock, myocardial infarction, and kidney failure indica-
tive of enhanced formation in these diseases [4]. More-
over, the bioactivity of ET-1 triggers vasoconstriction
and pro-inflammatory action which have been impli-
cated in the pathogenesis of hypertension and vascular
diseases [3-6]. The effects of ET-1 are mediated through
a G protein-dependent regulation, including two types of
ET receptors: ET type A (ETA) and type B (ETB) [7].
ETA is involved in constriction and proliferation of
vascular smooth muscle cells, whereas ETB on endothe-
lial cells mediates the generation of nitric oxide, which
acts as vasodilator and inhibits platelet aggregation [8].
Moreover, ET-1 also plays a substantial role in the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(CNS) diseases. In brain, endothelial cells [9] and astro-
cytes [10] are potential sources of ET-1 release in re-
sponse to hypoxic/ischemic injury of the brain. A report
has shown that the ETB receptors are located on brain
endothelial and vascular smooth muscle cells, and
modulate post-injury responses of these cells in the CNS
[6]. Thus, there is an increasing interest in the regulatory
role of endothelial cells in neurovascular coupling, which
matches adequate supply of cerebral blood flow with the
local metabolic demands that are imposed by neural ac-
tivity [11]. As a fundamental component of the neuro-
vascular unit, endothelial dysfunction has been shown to
be implicated in neurodegenerative diseases [11,12]. Cir-
cumstantial evidence has further demonstrated that
overexpression of ET-1 on endothelial cells has deleteri-
ous effects on ischemic brain [1]. It has been demon-
strated that endothelial ET-1 induces cytokines or
chemokines (e.g., interleukine-1 or interleukin-8) pro-
duction and secretion by non-neuronal cells, including
astrocytes and human brain-derived endothelial cells,
which directly contributes to BBB breakdown during
CNS inflammation [11,13]. These findings suggest that
ET-1 might be involved in neuroinflammation. However,
the detailed mechanisms responsible for ET-1 action are
still limited.
Cyclooxygenase (COX), known as prostaglandin-
endoperoxide synthase, is a rate-limiting key enzyme in
the synthesis of prostaglandins (PGs). In this process,
phospholipase A2 catalyzes the release of arachidonic
acid (AA) from membrane phospholipids, while COX
catalyzes the conversion of AA into PGs [14,15]. COX
exists two isoforms: COX-1, which is constitutively
expressed under normal conditions in most tissues,
mediates regulating normal physiological responses and
controls vascular homeostasis; COX-2, is not detectable
in most normal tissues or cells, but its expression can be
induced by a variety of stimuli such as cytokines, endo-
toxin, and growth factors to produce PGs during inflam-
matory responses in various cell types like vascular
endothelial and smooth muscle cells [16,17]. Previous
reports have shown that COX-2 immunoreactivity is a
characteristic finding in the synovial macrophage and
vascular cells of patients with arthritis and atheroscler-
osis, respectively. Moreover, several studies have indi-
cated COX-2 as a major therapeutic target for the
treatment of inflammatory disorders like arthritis [14].
The mice with homozygous deletion of the cox-2 gene
lead to a striking reduction of endotoxin-induced in-
flammation [18]. Accordingly, COX-2 may play a cru-
cial role in the development of various inflammatory
responses including vascular inflammation. In the
CNS, several studies have indicated that up-regulation
of COX-2 leads to production of PGs which are potentinflammatory mediators in neurodegenerative disor-
ders [19].
ET-1 is known to activate ET receptors (ETA or ETB),
a heterotrimeric G protein-coupled receptor (GPCR),
which stimulate multiple signaling pathways and regu-
late diverse cellular functions [7,20-22]. The principal
mechanism underlying activation by ET-1 is mediated
through ETB receptors coupling Gq proteins, resulting in
activation of phospholipase C (PLC)-β, phosphoinositide
(PI) hydrolysis, and formation of inositol trisphosphate
(IP3) and diacylglycerol, leading to Ca
2+ increase and
protein kinase C (PKC) activation [22]. Activation of a
Gi protein-coupled ETB receptor has been also shown to
inhibit adenylyl cyclase activity [23]. Additionally, several
studies have demonstrated that activation of Gq and Gi
protein-coupled receptors via different signal pathways
could activate diverse mitogen-activated protein kinases
(MAPKs) [24]. It has been shown that ET-1-stimulated
MAPKs activation to regulate various cellular responses
including cell survival, growth, proliferation, and cellular
hypertrophy in several cell types [21,25]. Several studies
have suggested that up-regulation of COX-2 requires ac-
tivation of MAPKs and related transcription factors in
various cell types [22,26,27]. Our previous reports also
demonstrate that several GPCR agonists (e.g. sphingo-
sine 1-phosphate, thrombin, and bradykinin) stimulate
MAPKs and NF-κB activation associated with COX-2
expression in rat VSMCs and astrocytes [28,29]. Al-
though several pro-inflammatory mediators have been
extensively confirmed to rapidly up-regulate NF-κB-
dependent genes such as COX-2 and play a critical role
in inflammation [29,30], the signaling mechanisms by
which ET-1-induced MAPKs activation linked to COX-2
expression and PGE2 production are not completely
defined in brain microvascular endothelial cells.
In this study, we investigated the molecular mechan-
isms underlying ET-1-induced COX-2 expression in
mouse brain microvascular endothelial (bEnd.3) cells.
These findings suggested that ET-1 induces COX-2 ex-
pression at the transcriptional and translational levels,
which is mediated through the ETB receptor (coupling
to Gi and Gq)-dependent activation of ERK1/2, p38
MAPK, JNK1/2, and NF-κB pathway, leading to PGE2
biosynthesis in mouse bEnd.3 cells. These results pro-
vide new insights into the mechanisms of ET-1 action
which may be therapeutic value in brain inflammatory
diseases.
Results
ET-1 induces COX-2 expression and PGE2 release in
bEnd.3 cells
To investigate the effect of ET-1 on COX-2/PGE2 sys-
tem, bEnd.3 cells were incubated with various concen-
trations of ET-1 for the indicated time intervals. The
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time- and concentration-dependent manner (Figure 1A).
There was a significant increase within 2-4 h, reached a
maximal response within 6 h, and declined within 24 h.
ET-1 also time-dependently induced COX-2 mRNA ex-
pression in bEnd.3 cells, determined by RT-PCR
(Figure 1B). There was a significant increase in COX-2
mRNA within 30 min, and reached a maximal response
within 2 h. Moreover, to confirm whether ET-1 induces
COX-2 expression via the transcription activity of COX-
2 promoter, cells were transiently transfected with COX-
2 promoter-luciferase reporter construct and then sti-
mulated with ET-1 for the indicated time intervals. As
shown in Figure 1C, ET-1 time-dependently induced
COX-2 promoter-luciferase activity in bEnd.3 cells. A
maximal response was obtained within 4 h. Our previous
studies have shown that COX-2 expression induced by
BK or sphingosine 1-phosphate is mainly responsible for
prostanoid (PGE2) release in various cell types [28,29].
Thus, to determine whether ET-1 could induce PGE2Figure 1 ET-1 induced COX-2 expression and PGE2 release. (A) Time a
were treated with various concentration ET-1 for the indicated time interva
cells were treated with 10 nM ET-1 for the indicated time intervals. COX-2
COX-2 promoter transcription activity, cells were transfected a COX-2 prom
indicated times. The promoter reporter assay was performed as described
conditioned media were collected to assay PGE2 level by EIA as described
compared with vehicle).biosynthesis, we collected the conditioned media and
determined PGE2 levels by using an EIA kit. The results
showed that ET-1 time-dependently stimulated PGE2 re-
lease (Figure 1D) and a significant PGE2 production was
observed within 4 h, reached a maximal response within
6 h and slightly declined within 24 h. These results sug-
gested that ET-1 induces COX-2/PGE2 system via up-
regulating COX-2 gene expression in bEnd.3 cells.
ET-1 upregulates COX-2 expression via an ETB receptor
ET-1 exerts its biological effects via ET receptors, including
ETA and ETB, which are members of GPCR superfamily [7].
First, we determined which subtypes of ET receptors are
expressed on bEnd.3 cells by RT-PCR. The data showed that
ETB but not ETA receptors are expressed on bEnd.3 cells
(Figure 2A). Next, to identify the subtypes of ET receptors
involved in ET-1-induced COX-2 expression, pretreatment
with BQ-788 (an ETB antagonist), but not BQ-123 (an ETA
antagonist), attenuated the ET-1-induced COX-2 protein
(Figure 2B) and mRNA (Figure 2C) expression, suggestingnd concentration dependence of ET-1-induced COX-2 expression, cells
ls. (B) Time dependence of ET-1-induced COX-2 mRNA expression,
mRNA was analyzed by RT-PCR. (C) Time dependence of ET-1-induced
oter–luciferase reporter gene and then incubated with ET-1 for the
in “Materials and Methods”. (D) PGE2 release induced by ET-1, the
in “Materials and Methods” (n=3 in each group; *P<0.05, #P<0.01
Figure 2 Involvement of ETB receptors in ET-1-induced COX-2 expression. (A) RT-PCR analysis of ET receptor expression in bEnd.3 cells. Lane
1: maker. Lane 2: ETA primers and bEnd.3 RNA. Lane 3: ETB primers and bEnd.3 RNA. (B, C) Cells were pretreated with BQ-123 or BQ-788 for 1 h
and then incubated with ET-1 for (B) 6 h and (C) 1 h. (D) Cells were transfected with siRNA for ETB receptor for 24 h and then exposed to ET-1
for 6 h. The (B, D) COX-2 protein and (C) mRNA were analyzed by Western blot and RT-PCR, respectively as described in Figure 1. Data are
expressed as mean ± SEM of three individual experiments (n=3 in each group, #P<0.01 as compared with cells stimulated by ET-1 alone).
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responses. To further confirm this note, transfection of cells
with ETB siRNA significantly down-regulated ETB protein
expression and inhibited ET-1-induecd COX-2 expression
(Figure 2D). These data suggested that ET-1-induced COX-
2 expression is mediated through an ETB receptor-
dependent manner in these cells.
Involvement of a Gi and Gq protein-coupled ETB receptor
in ET-1-induecd COX-2 expression
ET receptor has been shown to be a pleiotropic GPCR for
ET-1 which is coupled to G proteins including Gi and Gq[7,22]. To further determine which of G proteins was
involved in ET-1-induced COX-2 expression, pretreatment
with either Gi protein antagonist GP antagonist-2 (GPA2)
or Gq protein antagonist GP antagonist-2A (GPA2A) con-
centration-dependently attenuated ET-1-induced COX-2
protein (Figure 3A) and mRNA (Figure 3B) expression. Fur-
thermore, to confirm these results, as shown in Figure 3C
and D, transfection with either Giα or Gqα down-regulated
Giα or Gqα protein, respectively, and attenuated ET-1-
induced COX-2 expression. These data demonstrated that
ET-1-induced COX-2 expression is mediated through either
Gi or Gq protein-coupled ETB receptors in bEnd.3 cells.
Figure 3 ET-1 induces COX-2 expression via a Gi and Gq proteins-coupled ETB receptor. (A, B) Cells were pretreated with Gi antagonist
(GPA2) or Gq antagonist (GPA2A) for 1 h and then exposed to ET-1 for (A) 6 h and (B) 1 h. (C, D) Cells were transfected with siRNA for (C) Giα or
(D) Gqα protein for 24 h and then exposed to ET-1 for 6 h. The (A, C, D) COX-2 protein and (B) mRNA were analyzed by Western blot and RT-
PCR, respectively as described in Figure 1. Data are expressed as mean ± SEM of three individual experiments (n=3 in each group, #P<0.01 as
compared with ET-1 alone).
Lin et al. Cell Communication and Signaling 2013, 11:8 Page 5 of 14
http://www.biosignaling.com/content/11/1/8ET-1-induced COX-2 expression is mediated through
MAPKs
Activation of MAPKs by ET-1 could modulate cellular
functions of endothelial cells [31]. To investigate the
roles of ERK1/2, p38 MAPK, and JNK1/2 in ET-1-
induced COX-2 expression, pretreatment with the in-
hibitor of MEK1/2 (U0126), p38 MAPK (SB202190), or
JNK1/2 (SP600125) attenuated ET-1-induced COX-2
protein (Figure 4A) and mRNA (Figure 4B) expression
in bEnd.3 cells, suggesting the involvement of ERK1/2,
p38 MAPK, and JNK1/2 in ET-1-induced responses. To
further determine whether ET-1-stimulated ERK1/2, p38
MAPK, and JNK1/2 phosphorylation is involved in
COX-2 expression, as shown in Figure 4C, ET-1 time-
dependently stimulated ERK1/2, p38 MAPK, and JNK1/2 phosphorylation which was attenuated by pretreatment
with U0126, SB202190, or SP600125 during the period
of observation. Moreover, to ensure the roles of MAPKs
in ET-1-induced COX-2 expression, transfection with
siRNA of ERK2, p38 MAPK, or JNK1 down-regulated
the expression of total ERK2, p38 MAPK, or JNK1 pro-
tein and attenuated ET-1-induced COX-2 expression
(Figure 4D). These data indicated that phosphorylation
of ERK1/2, p38 MAPK, and JNK1/2 is involved in ET-1-
induced COX-2 expression in bEnd.3 cells. To demon-
strate whether ET-1 stimulates ERK1/2, p38 MAPK, and
JNK1/2 phosphorylation via a G protein-coupled ETB re-
ceptor cascade, pretreatment with BQ-788, GPA2, or
GPA2A attenuated ET-1-stimulated ERK1/2, p38
MAPK, and JNK1/2 phosphorylation during the period
Figure 4 (See legend on next page.)
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Figure 4 ET-1-induced COX-2 expression is mediated through MAPKs phosphorylation. (A, B) Cells were treated with 10 nM ET-1 for (A) 6
h and (B) 1 h in the absence or presence of U0126, SB202190, or SP600125. The COX-2 protein and mRNA expression were determined by
Western blot and RT-PCR. (C) Time dependence of ET-1-stimulated ERK1/2, p38 MAPK, and JNK1/2 phosphorylation, cells were incubated with 10
nM ET-1 for the indicated times in the absence or presence of U0126 (1 μM), SB202190 (300 nM), or SP600125 (300 nM). (D) Cells were
transfected with siRNA of ERK2, p38 MAPK, or JNK1 and then exposed to ET-1 for 6 h. (E) Cells were pretreated with BQ-788 (1 μM), GPA2 (1 μM),
or GPA2A (1 μM) for 1 h and then incubated with ET-1 (10 nM) for the indicated times. The cell lysates were collected and analyzed by Western
blotting using an anti-COX-2, anti-phospho-ERK1/2, anti-phospho-p38 MAPK, anti-phospho-JNK1/2, anti-ERK2, anti-p38 MAPK, anti-JNK1, or anti-
GAPDH (as an internal control) antibody. Data are expressed as mean ± SEM of at least three individual experiments (n=3 in each group; *P<0.05,
#P<0.01 as compared with ET-1 alone).
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that G(i/q) protein-coupled ETB-dependent activation of
ERK1/2, p38 MAPK, and JNK1/2 by ET-1 is, at least in
part, required for COX-2 expression in bEnd.3 cells.
NF-κB is required for ET-1-induced COX-2 expression
ET-1 has been shown to modulate cellular functions
through activation of NF-κB signaling in various cell
types [32]. To examine whether activation of NF-κB is
required for ET-1-induced COX-2 expression, as shown
in Figure 5A and B, pretreatment with a selective NF-κB
inhibitor Bay11-7082, which blocks activation of NF-κB
signaling, attenuated ET-1-induced COX-2 protein and
mRNA expression in bEnd.3 cells. To determine
whether the involvement of NF-κB in ET-1-induced
responses mediated through NF-κB (p65 subunit) trans-
location, as shown in Figure 5C, ET-1 time-dependently
stimulated translocation of NF-κB p65 from cytosol into
nucleus determined by Western blot. A maximal re-
sponse was obtained within 90 min and sustained over
120 min (upper part). Moreover, we also confirmed the
NF-κB p65 translocation by an immunofluorescence
staining. The imaging data confirmed that ET-1 stimu-
lated the p65 translocation at 90 min, which was inhib-
ited by pretreatment with Bay11-7082 (Figure 5C, lower
part). We further demonstrated that ET-1 stimulated
translocation of NF-κB p65 was attenuated by pretreat-
ment with the inhibitor of ETB receptor (BQ-788),
MEK1/2 (U0126), p38 MAPK (SB202190), JNK1/2
(SP600125), or NF-κB (Bay11-7082) (Figure 5D). To fur-
ther verify that NF-κB p65 is essential for ET-1-induced
COX-2 expression, as shown in Figure 5E, transfection
with p65 siRNA significantly reduced the p65 protein
expression (upper panel) and the ET-1-induced COX-2
expression (lower panel). The results suggested that ET-
1-stimulated NF-κB translocation mediated through ETB
receptor, ERK1/2, p38 MAPK, and JNK1/2 is required
for COX-2 induction in bEnd.3 cells.
Involvement of NF-κB in COX-2 gene promoter activity
stimulated by ET-1
We have found that ET-1 stimulates translocation of
NF-κB p65 leading to COX-2 expression (Figure 5).
Next, we examined whether activation of NF-κB isessential for ET-1-induced COX-2 gene up-regulation.
The transcriptional activity of NF-κB was evaluated by a
promoter (containing NF-κB binding sites)-luciferase ac-
tivity assay. As shown in Figure 6A, ET-1 enhanced NF-
κB transcriptional activity in a time-dependent manner
with a maximal response within 60 min, which was sig-
nificantly inhibited by pretreatment with an inhibitor of
NF-κB (Bay11-7082, 10 nM). Moreover, pretreatment
with BQ-788 (1 μM), GPA2 (1 μM), GPA2A (1 μM),
U0126 (U0, 1 μM), SB202190 (SB, 300 nM), or
SP600125 (SP, 300 nM) attenuated NF-κB transcriptional
activity stimulated by ET-1 (Figure 6B), demonstrating
that ET-1 enhances the NF-κB transcriptional activity
through an ETB-dependent activation of MAPKs. Subse-
quently, we determined that ET-1-stimulates NF-κB p65
binding activity in a time-dependent manner by ChIP-
PCR analysis (Figure 6C). ET-1-stimulated NF-κB p65
binding activity was inhibited by pretreatment with
U0126, SB202190, SP600125, Bay11-7082, or BQ-788
(Figure 6C, lower part). In addition, we have demon-
strated that ET-1 time-dependently induces COX-2 pro-
moter activity (Figure 1C). We further demonstrated
that ET-1-increased the COX-2 promoter activity was
significantly inhibited by pretreatment with BQ-788,
GPA2, GPA2A, U0126, SB202190, SP600125, or Bay11-
7082 (Figure 6D), suggesting that ET-1 stimulates COX-
2 promoter activity via the ETB-dependent activation of
MAPKs and NF-κB in bEnd.3 cells. To further ensure
that NF-κB indeed mediates ET-1-induced COX-2 pro-
moter activity through binding to its regulatory element
within the COX-2 promoter region, the wild-type (WT)
and mutated by a single-point mutation of the NF-κB
binding site (mt-κB) COX-2 promoters were constructed
(as illustrated in Figure 6E, upper panel). ET-1-
stimulated COX-2 promoter activity was significantly
attenuated in bEnd.3 cells transfected with mt-κB-COX-
2 (Figure 6D, lower panel), indicating that NF-κB elem-
ent was essential for ET-1-induced COX-2 promoter ac-
tivity. These results further confirmed that ET-1 induces
COX-2 promoter activity via enhancing NF-κB binding
to the κB binging site within COX-2 promoter region in
bEnd.3 cells.
We have found that ET-1 time-dependently induces
PGE2 release (Figure 1D). Here, we further determined
Figure 5 NF-κB (p65) is essential for ET1-1-induced COX-2 expression. (A, B) Cells were treated with 10 nM ET-1 for 6 h in the absence or
presence of Bay11-7082. The COX-2 protein and mRNA expression were determined by Western blot and RT-PCR as described in Figure 1.
(C) Time dependence of ET-1-stimulated p65 NF-κB translocation by subcellular isolation, Western blot, and immunofluorescent stain. (D) Cells
were pretreated with U0126 (1 μM), SB202190 (300 nM), SP600125 (300 nM), BQ-788 (1 μM), or Bay11-7082 (10 nM) for 1 h and then incubated
with ET-1 (10 nM) for 90 min. The nuclear fraction was analyzed by Western blot. (E) Cells were transfected with p65 siRNA and then exposed to
ET-1 for 6 h. The cell lysates were collected and analyzed by Western blotting using an anti-COX-2, anti-p65, anti-Lamin A, or anti-GAPDH
(as an internal control) antibody. Data are expressed as mean ± SEM of at least three individual experiments (n=3 in each group; #P<0.01 as
compared with ET-1 alone).
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induced PGE2 release, as shown in Figure 6F, ET-1-
induced PGE2 release was markedly attenuated by pre-
treatment with BQ-788, GPA2, GPA2A, U0126,
SB202190, SP600125, Bay11-7082, or transfection with
p65 siRNA. These results demonstrated that ETB-
mediated activation of MAPKs (i.e., ERK, p38 MAPK,
and JNK) and NF-κB by ET-1 is essential for COX-2 up-
regulation and PGE2 release in bEnd.3 cells.
Discussion
Several lines of evidence have demonstrated that high
levels of PGs, synthesized by inducible COX-2, areinvolved in inflammatory responses. The up-regulation
of COX-2 has been shown to display a wide range of
biological activities in different tissues, including devel-
opment, proliferation, cancers, and inflammation
[14,15]. Moreover, ET-1 is elevated in the regions of vas-
cular injuries and inflammation [7,8]. Circumstantial evi-
dence has further demonstrated that overexpression of
ET-1 on endothelial cells has deleterious effects on is-
chemic brain [1,5,6]. Reid et al. (1995) suggest that the
ET-1 model provides new insights into the mechanisms
of cerebral ischemia and reperfusion injury, and evalu-
ates the usefulness of novel strategies of neuroprotection
[33]. ET-1 has been shown to up-regulate the expression
Figure 6 ET-1-stimulated COX-2 promoter activity is mediated through NF-κB-dependent pathway. (A) Time dependence of ET-1-
enhanced NF-κB transcription activity, cells were transfected with a NF-κB-luciferase reporter gene and then exposed to ET-1 for the indicated
times. (B) After transfection, the cells were pretreated with BQ-788 (1 μM), GPA2 (1 μM), GPA2A (1 μM), U0126 (1 μM), SB202190 (300 nM),
SP600125 (300 nM), or (A) Bay11-7082 (10 nM) for 1 h and then incubated with ET-1 (10 nM) for 60 min. (C) Cells were pretreated with BQ-788,
U0126, SB202190, or SP600125 for 1 h and then incubated with ET-1. The p65 NF-κB binding activity was analyzed by ChIP-PCR as described in
Methods. (D) For COX-2 promoter activity, cells were transfected with a COX-2-promoter-luciferase reporter gene and then exposed to ET-1. After
transfection, the cells were pretreated with BQ-788, GPA2, GPA2A, U0126, SB202190, SP600125, or Bay11-7082 for 1 h and then incubated with
ET-1 for 6 h. (E) Schematic representation of a 50-promoter regions of the mouse different COX-2 promoter constructs, either wild-type (WT) or
mutation of the κB-binding site (mt-κB) fused to the pGL-luciferase reporter gene, the translational start site (+1) of the luciferase reporter gene
was indicated by an arrow. Cells were transfected with WT COX-2 promoter reporter gene (WT-COX-2) or NF-κB mutated COX-2 promoter
reporter gene (mt-κB-COX-2) and then incubated with or without ET-1 for 6 h. The promoter reporter assay was performed as described in
Methods. (F) Cells were pretreated with BQ-123, BQ-788, GPA2, GPA2A, U0126, SB202190, SP600125, Bay11-7082, or transfected with p65 siRNA
and then incubated with ET-1 for 6 h. The PGE2 levels were analyzed by EIA. Data are expressed as mean ± SEM of at least three individual
experiments (n=3 in each group; #P<0.01 as compared with ET-1 alone).
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[26,27,34]. However, little is known about the effect of
ET-1 on COX-2 expression in brain vascular endothelial
cells. Here, we applied cultured models of mouse bEnd.3
cells coupled with Western blot analysis, selective
pharmacological inhibitors, transfection with siRNAs,
immunofluorescenct staining, and promoter assay to in-
vestigate the molecular mechanisms underlying ET-1-
induced COX-2 expression and PGE2 release. Our
results demonstrate that in bEnd.3 cells, activation of
ETB receptor-dependent MAPKs (ERK1/2, p38, and
JNK1/2) and NF-κB signaling cascade is essential for
ET-1-induced COX-2 gene expression and PGE2 release.
ET-1 activates ET receptor subtypes (ETA and ETB) which
are coupled to various G proteins such as Gq and Gi and
then lead to multiple signaling pathways and regulate di-
verse cellular functions [7,20-22]. Thus, we first demon-
strated a significant expression of ETB receptor in mouse
bEnd.3 cells (Figure 2A). The involvement of ETB receptors
in these responses is confirmed by that pretreatment with
BQ-788 (an ETB receptor antagonist) reduced the ET-1-
induced COX-2 protein and mRNA expression (Figure 2B
and 2C), promoter activity (Figure 6D), and PGE2 release
(Figure 6F), but not by an ETA receptor antagonist BQ-123.
Subsequently, we confirmed these results by transfection
with ETB siRNA (Figure 2D), suggesting that ETB receptor
predominantly mediates ET-1-induced COX-2 expression
and PGE2 release in bEnd.3 cells. Next, several subtypes of
G proteins are potentially implicated in ET-1-induced COX-
2 expression. We use GPA2 (a Gi protein antagonist) and
GPA2A (a Gq protein antagonist) to interrupt G protein sig-
naling and consequent COX-2 expression (Figure 3A).
Moreover, the inhibitory effects of GPA2 and GPA2A on
COX-2 induction by ET-1 were also observed in its mRNA
(Figure 3B), promoter activity (Figure 6D), and PGE2 release
(Figure 6F), indicating that ET-1-induced COX-2 expression
and PGE2 release is mediated through a GPCR (i.e. ETB)
coupling to either Gi or Gq protein in bEnd.3 cells, consist-
ent with previous studies from esophageal smooth muscle
cells [34] and rat brain astrocytes [22]. In contrast, previous
reports have shown that ET-1 induces COX-2 expression
via ETA receptors in peripheral lung microvascular smooth
muscle cells [25] and ET-1 (ETA) receptors linked to
phospholipase C and phospholipase A2 activation and pros-
tanoid secretion (e.g. PGE2) in cultured human brain micro-
vascular endothelial cells [35,36]. However, in respiratory
and cardiovascular systems, both ET receptor subtypes, ETA
in particular, are involved in progression of several diseases
[37,38]. There differences may be due to cell type specific or
different experimental conditions.
Abnormal MAPK regulation might be implicated in
several models of CNS injury and inflammation [39].
Several lines of evidence demonstrate that MAPKs could
be activated by GPCR agonists through differentsignaling pathways [24]. MAPKs activation by ET-1 has
been shown to modulate various cellular responses in
several cell types [22,25]. Activation of ERK1/2 (p44/p42
MAPK) might be implicated in the expression of inflam-
matory genes in several models of vascular injury and
inflammation [17,28]. In this study, we demonstrated
that ET-1 stimulated an ETB receptor-dependent cascade
of sequential ERK1/2 phosphorylation (Figure 4E), which
contributes to induction of COX-2 protein and mRNA
levels (Figure 4A and 4B), promoter activity (Figure 6D),
and PGE2 release (Figure 6F). The involvement of ERK1/
2 in COX-2 expression and PGE2 release was furthe
confirmed by transfection of cells with p42 siRNA
(Figure 4D). These results are consistent with those of
obtained with COX-2 expression induced by BK, throm-
bin, or ET-1 in various cell types [17,26,28]. Additionally,
we found that expression of COX-2 and release of PGE2
induced by ET-1 were also attenuated by the inhibitor of
p38 MAPK or JNK1/2. Pretreatment with SB202190 or
SP600125 both markedly reduced ET-1-induced ex-
pression of COX-2 protein and mRNA (Figure 4A and
4B), promoter activity (Figure 6D), and PGE2 release
(Figure 6F). Moreover, we also demonstrated that ET-1
stimulates phosphorylation of p38 MAPK and JNK via
an ETB-dependent manner (Figure 4C and 4E). Similarly,
we further confirmed these results by transfection with
siRNA for p38 MAPK or JNK1 that attenuated ET-1-
induced COX-2 expression (Figure 4D). These data
clearly indicated that in bEnd.3 cells, three MAPK cas-
cades (i.e. ERK1/2, p38 MAPK, and JNK1/2) are
required for ET-1-induced COX-2 expression and
PGE2 release. These results are consistent with those
of obtained with up-regulation of COX-2 by ET-1 via
p38 MAPK in glomerular mesangial cells or esophageal
smooth muscle cells [27,34]. For the role of JNK1/2,
we are the first presented that JNK1/2 plays a critical
role in induction of COX-2 by ET-1 in endothelial
(bEnd.3) cells.
It has been well established that inflammatory responses
following exposure to extracellular stimuli are highly
dependent on activation of NF-κB transcription factor,
which plays an important role in regulation of several gene
expression [40]. The 5’-flanking region of the COX-2 pro-
moter has been shown to contain several binding sequences
for various transcription factors including NF-κB [41].
Therefore, the regulation of COX-2 transcription may be
mediated by aberrant activation of several distinct transcrip-
tion factors dependent on agonists [29,42]. These reports
suggest that NF-κB plays a critical role in the regulation of
COX-2 expression in the development of the inflammatory
responses. Our data showed that ET-1-induced COX-2 gene
expression and PGE2 release was significantly abolished by a
selective NF-κB inhibitor Bay11-7082 (Figures 5 and 6) or
NF-κB p65 siRNA (Figures 5E and 6F), suggesting that NF-
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bEnd.3 cells. Moreover, ET-1-stimulated NF-κB p65 trans-
location (Figure 5C), binding to COX-2 promoter region
(Figure 6C and 6E), and NF-κB transcriptional activity
(Figure 6A) was significantly inhibited by Bay11-7082 and
the MAPK inhibitor U0126 (MEK1/2), SB202190 (p38
MAPK), or SP600125 (JNK1/2) (Figures 5 and 6). Our data
further showed that ET-1-stimulated NF-κB transcriptio-
nal activity was significantly attenuated by blocking Gi and
Gq protein-coupled ETB receptor-dependent pathways
(Figure 6B), indicating that ET-1-induced activation of NF-
κB is mediated through ETB receptor-dependent activation
of three MAPKs cascades. These findings are consistent
with recent studies indicating that COX-2 expression and
prostacyclin release induced by thrombin were mediated
through MAPKs and NF-κB activation in endothelial cells
[16] and vascular smooth muscle cells [17] and COX-2 ex-
pression and PGE2 release induced by BK via ERK1/2 link-
ing to NF-κB activation in astrocytes [29]. The involvement
of NF-κB in ET-1-induced COX-2 expression is also consist-
ent with previous reports indicating that ET-1-stimulated
activation of NF-κB regulates expression of target genes
involved in various CNS inflammatory processes [22]. More-
over, our recent data have also demonstrated that in bEnd.3
cells, c-Src-dependent transactivation of EGFR/PI3K/Akt
and MAPKs linking to c-Jun/AP-1 cascade is essential for
ET-1-induced COX-2/PGE2 upregulation [43]. We suggest
that the findings of these two studies might have a crosstalk
in MAPKs and lead to COX-2 expression induced by ET-1
in these cells. The interplay between these two pathways in
the induction of COX-2 will be investigated in the future.
Conclusions
In this study, we reported here that ET-1/ET (ETB) receptor
system exerts its effects on COX-2 gene expression and
PGE2 release in mouse bEnd.3 cells. The Gi and Gq protein-
coupled ETB receptor, ERK1/2, p38 MAPK, JNK1/2, and
NF-κB cascades cooperatively mediated these effects of ET-
1. These findings concerning ET-1-induced COX-2/PGE2
system imply that ET-1 might play a critical role in brain in-
jury, vascular inflammation, and CNS diseases, mediated
through MAPK-dependent activation of NF-κB pathway in
bEnd.3 cells. Pharmacological approaches suggest that tar-
geting COX-2/PGE2 system and their upstream signaling
components should yield useful therapeutic targets for brain
injury and inflammatory diseases.
Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM)/F-12
medium, fetal bovine serum (FBS), and TRIzol were
from Invitrogen (Carlsbad, CA). Hybond C membrane
and enhanced chemiluminescence (ECL) Western blot
detection system were from GE Healthcare Biosciences(Buckinghamshire, UK). Anti-COX-2 monoclonal anti-
body was from BD Transduction Laboratories (San
Diego, CA). Phospho-ERK1/2, phospho-p38, phospho-
JNK1/2 antibody kits were from Cell Signaling (Danver,
MA). p65, p42 (ERK2), p38, and JNK1 antibodies were
from Santa Cruz (Santa Cruz, CA). Anti-glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) antibody was
from Biogenesis (Boumemouth, UK). BQ-123, BQ-788,
GP antagonist-2, GP antagonist-2A, U0126, SB202190,
SP600125, and Bay11-7082 were from Biomol (Plymouth
Meeting, PA). Bicinchoninic acid (BCA) protein assay
reagent was from Pierce (Rockford, IL). ET-1, enzymes,
and other chemicals were from Sigma (St. Louis, MO).
Mouse brain microvascular endothelial cell culture
Mouse brain microvascular endothelial cells (bEnd.3)
were purchased from Bioresource Collection and Re-
search Centre (BCRC, Hsinchu, Taiwan) and grew in
DMEM/F-12 containing 10% FBS and antibiotics (100
U/ml penicillin G, 100 μg/ml streptomycin and 250 ng/
ml fungizone) at 37°C in a humidified 5% CO2 atmos-
phere. The cell line is acquired from mouse BALB/c
strain brain cerebral cortex endothelial polyoma middle
T antigen transformed, which was performed STR-PCR
profile at BCRC. All the experiments were performed
using this cell line and approved by the ethic approval of
Chang Gung University. Confluencent cells were
released with 0.05% (w/v) trypsin/0.53 mM EDTA for 5
min at 37°C. The cell suspension (2 × 105 cells/ml) was
plated onto 6-well culture plates (2 ml/well) or 10-cm
culture dishes (10 ml/dish) for the measurement of pro-
tein or RNA expression, respectively. Culture medium
was changed after 24 h and then every 3 days. Experi-
ments were performed with cells from passages 5 to 13.
Preparation of cell extracts and Western blot analysis
Growth-arrested cells were incubated with ET-1 at 37°C
for various time intervals. The cells were washed with
ice-cold phosphate-buffered saline (PBS), scraped, and
collected by centrifugation at 45,000 × g for 1 h at 4°C
to yield the whole cell extract, as previously described
[17]. Samples were analyzed by Western blot, transferred
to nitrocellulose membrane, and then incubated over-
night using an anti-COX-2, phospho-ERK1/2, phospho-
p38 MAPK, phospho-JNK1/2, p42, p38, JNK1, p65, or
GAPDH antibody. Membranes were washed with TTBS
four times for 5 min each, incubated with a 1:2000 dilu-
tion of anti-rabbit horseradish peroxidase antibody for
1 h. The immunoreactive bands were detected by ECL
reagents.
Total RNA extraction and gene expression
For reverse transcription PCR (RT-PCR) analysis, total
RNA was extracted from mouse brain endothelial cells
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cDNA obtained from 0.5 μg total RNA was used as a
template for PCR amplification. Oligonucleotide primers
were designed based on Genbank entries for mouse
COX-2 and β-actin. The following primers were used for
amplification reaction: for COX-2: 50-(AAAACCGTGGG
GAATGTATGAGC)-30 (sense), 50-(GATGGGTGAAGT
GCTGGGGAAAG)-30 (anti-sense); ETA: 5
0-(GGCGCA
ATCGCTGACAATGCTGAG)-30 (sense), 50-(CCACGTA






mixes contained 10 μl of 5X PCR buffer, 1.25 mM of each
dNTP, 100 pmol of each forward and reverse primer, and
2.5 units of Taq polymerase (Takara, Shiga, Japan). The final
reaction volume was 50 μl. Amplification was performed in
25 cycles at 94°C, 20 s; 60°C, 40 s; 72°C, 40 s [44]. After the
last cycle, all samples were incubated for an additional 10
min at 72°C. PCR fragments were analyzed on 2% agarose
1X TAE gel containing ethidium bromide and their size
was compared to a molecular weight marker. Amplification
of β-actin, a relatively invariant internal reference RNA,
was performed in parallel, and cDNA amounts were stan-
dardized to equivalent β-actin mRNA levels. These primer
sets specifically recognized only the genes of interest as
indicated by amplification of a single band of the expected
size (500 bp for COX-2, 343 bp for ETA; 293 bp for ETB,
and 514 bp for β-actin) and direct sequence analysis of the
PCR products.Immunofluorescence staining
Cells were plated on 6-well culture plates with coverslips.
Cells were shifted to a serum-free DMEM/F-12 for 24 h
and treated with 10 nM ET-1. After washing twice with
ice-cold PBS, the cells were fixed with 4% (w/v) parafor-
maldehyde in PBS for 30 min, and then permeabilized
with 0.3% Triton X-100 in PBS for 15 min. The staining
was performed by incubating with 10% normal goat serum
in PBS for 30 min followed by incubating with a primary
anti-p65 NF-κB polyclonal antibody (1:200 dilution) for 1
h in PBS with 1% BSA, washing thrice with PBS, incubat-
ing for 1 h with fluorescein isothiocyanate (FITC)-conju-
gated goat anti-rabbit antibody (1:200 dilution) in PBS
with 1% BSA, washing thrice with PBS, and finally mount-
ing with aqueous mounting medium. The images
observed under a fluorescence microscope (ZEISS, Axio-
vert 200M).Chromatin immunoprecipitation assay
To detect the in vivo association of nuclear proteins with
mouse COX-2 promoter, chromatin immunoprecipitation(ChIP) analysis was conducted as previously described [45].
Briefly, the bEnd.3 cells were cross-linked with 1% formalde-
hyde for 10 min at 37°C and washed thrice with ice-cold
PBS containing 1 mM phenylmethylsulfonyl fluoride
(PMSF) and 1% aprotinin. Soluble chromatin was prepared
using a ChIP assay kit (Upstate) according to the manufac-
turer’s recommendations and immunoprecipitated without
(control) or with anti-p65 NF-κB antibody and normal goat
immunoglobulin G (IgG). Following washes and elution,
precipitates were heated overnight at 65°C to reverse cross-
linking of DNA and protein. DNA fragments were purified
by phenol-chloroform extraction and ethanol precipitation.
The purified DNA was subjected to PCR amplification using
the primers specific for the region (-371 to +70) containing
the NF-κB binding site present in the COX-2 promoter re-
gion, sense primer: 50-GGGGGAGGGAAGCTGTGACAC
TCTTGAGCTTT-30; antisense primer: 50-GACAGTG
CTGAGATTCTTCGTGAGCAGAGTCC-30. PCR frag-
ments were analyzed on 2% agarose in 1X TAE gel con-
taining ethidium bromide and the size (441 bp) was
compared to a molecular weight marker.Plasmid construction, transient transfection and luciferase
assays
The mouse COX-2 promoter was constructed as
described previously [46] with some modifications. The
upstream region (-907 to +70) of the mouse COX-2 pro-
moter was cloned to the pGL3-basic vector containing
the luciferase reporter system. Introduction of a double-
point mutation into the NF-κB-binding site (TGGGGA
to TGGGAC) to generate pGL-COX2-mκB was per-
formed using the following (forward) primer: 50-GGG
GTACCGCAAATAATTTTTTATCAAACACTGTTTC
TG-30 (corresponding to a region from -907 to +70).
The underlined nucleotides indicate the positions of
substituted bases. The mutant construct was cloned into
the pGL3-basic vector containing the luciferase reporter
system. All plasmids were prepared by using QIAGEN
plasmid DNA preparation kits. The siRNAs for p42, p38,
JNK1, p65, and scrambled control were from Dharmacon
Research Inc (Lafayette, CO), and NF-κB or COX-2 pro-
moter constructs were transfected into cells using the
Lipofetamine-2000 transfection reagent according to the
instructions of manufacture (Invitrogen, Carlsbad, CA).
The transfection efficiency (~60%) was determined by
transfection with enhanced EGFP. To assess promoter
activity, cells were collected and disrupted by sonication
in lysis buffer (25 mM Tris-phosphate, pH 7.8, 2 mM
EDTA, 1% Triton X-100, and 10% glycerol). After cen-
trifugation, aliquots of the supernatants were tested for
luciferase activity using a luciferase assay system. Firefly
luciferase activities were standardized to β-galactosidase
activity.
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The cells were seeded in 12-well plates and grown to con-
fluence. Cells were shifted to serum-free DMEM/F-12
medium for 24 h, and then treated with ET-1 for various
time intervals. The culture supernatants were collected to
measure PGE2 levels using an EIA kit as specified by the
manufacturer (Cayman Chemical).
Statistical analysis of data
All data were estimated using GraphPad Prism Program
(GraphPad, San Diego, CA). Quantitative data were ana-
lyzed by one-way ANOVA followed by Tukey’s honestly
significant difference tests between individual groups.
Data were expressed as mean±SEM. A value of P<0.05
was considered significant.
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